{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:58:34Z","timestamp":1770821914844,"version":"3.50.1"},"reference-count":46,"publisher":"Akademiai Kiado Zrt.","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>Our objective was to compare the activity ceftazidime-avibactam (C\/A) and ceftolozane\u2013tazobactam (C\/T) against multidrug (including carbapenem) resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic> clinical isolates collected from six diagnostic centers in Hungary and to reveal the genetic background of their carbapenem resistance.<\/jats:p>\n        <jats:p>Two hundred and fifty consecutive, non-duplicate, carbapenem-resistant multidrug resistant (MDR) <jats:italic>P. aeruginosa<\/jats:italic> isolates were collected in 2017. Minimal inhibitory concentration values of ceftazidime, cefepime, piperacillin\/tazobactam, C\/A and C\/T were determined by broth microdilution method and gradient diffusion test. Carbapenem inactivation method (CIM) test was performed on all isolates. Carbapenemase-encoding <jats:italic>bla<\/jats:italic><jats:sub>VIM<\/jats:sub>, <jats:italic>bla<\/jats:italic><jats:sub>IMP<\/jats:sub>, <jats:italic>bla<\/jats:italic><jats:sub>KPC<\/jats:sub>, <jats:italic>bla<\/jats:italic><jats:sub>OXA-48-like<\/jats:sub> and <jats:italic>bla<\/jats:italic><jats:sub>NDM<\/jats:sub> genes were identified by multiplex PCR.<\/jats:p>\n        <jats:p>Of the isolates tested, 33.6% and 32.4% showed resistance to C\/A and C\/T, respectively. According to the CIM test results, 26% of the isolates were classified as carbapenemase producers. The susceptibility of <jats:italic>P. aeruginosa<\/jats:italic> isolates to C\/A and C\/T without carbapenemase production was 89% and 91%, respectively. Of the CIM-positive isolates, 80% were positive for <jats:italic>bla<\/jats:italic><jats:sub>VIM<\/jats:sub> and 11% for <jats:italic>bla<\/jats:italic><jats:sub>NDM<\/jats:sub>. The prevalence of Verona integron-encoded metallo-beta-lactamase (VIM)-type carbapenemase was 20.8%. NDM was present in 2.8% of the isolates.<\/jats:p>\n        <jats:p>Although the rate of carbapenemase-producing <jats:italic>P. aeruginosa<\/jats:italic> strains is high, a negative CIM result indicates that either C\/A or C\/T could be effective even if carbapenem resistance has been observed.<\/jats:p>","DOI":"10.1556\/030.2020.01152","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T14:14:58Z","timestamp":1585145698000},"page":"61-65","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":12,"title":["Ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary"],"prefix":"10.1556","volume":"67","author":[{"given":"Dustin","family":"O'Neall","sequence":"first","affiliation":[{"name":"1 Diagnostic Laboratory of Clinical Microbiology, Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emese","family":"Juh\u00e1sz","sequence":"additional","affiliation":[{"name":"1 Diagnostic Laboratory of Clinical Microbiology, Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1kos","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"2 National Public Health Institute, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"Urb\u00e1n","sequence":"additional","affiliation":[{"name":"3 Institute of Clinical Microbiology, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"4 Institute of Medical Microbiology, University of Debrecen, Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szilvia","family":"Melegh","sequence":"additional","affiliation":[{"name":"5 Department of Medical Microbiology and Immunology, Clinical Centre, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Katona","sequence":"additional","affiliation":[{"name":"6 Department of Microbiology, State Health Centre, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Krist\u00f3f","sequence":"additional","affiliation":[{"name":"1 Diagnostic Laboratory of Clinical Microbiology, Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref301","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buerhle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehman","year":"2013","journal-title":"J Bio Chem"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14787210.2016.1233060","article-title":"What is the role of the new \u03b2-lactam\/\u03b2-lactamase inhibitors ceftolozane\/tazobactam and ceftazidime\/avibactam?","volume":"14","author":"Gentile","year":"2016","journal-title":"Expert Rev Anti-infect Ther"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"e01589","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant pseudomonas aeruginosa isolates from Spain","volume":"61","author":"del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/1120009X.2016.1199506","article-title":"Carbapenem inactivation: a very affordable and highly specific method for phenotypic detection of carbapenemase-producing Pseudomonas aeruginosa isolates compared with other methods","volume":"29","author":"Akhi","year":"2017","journal-title":"J Chemother"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1128\/AAC.01768-15","article-title":"Comparison of verona integron-borne metallo-\u03b2-lactamase (VIM) variants reveals differences in stability and inhibition profiles","volume":"60","author":"Makena","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1469-0691.2007.01681.x","article-title":"Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium","volume":"13","author":"Mesaros","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/jac\/dkx253","article-title":"Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane\/tazobactam and comparison of different susceptibility testing methods","volume":"72","author":"Schaumberg","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref171","article-title":"The Carbapenem Inactivation Method (CIM), a simple and low-cost alternative for the carba NP test to assess phenotypic carbapenemase activity in gram-negative rods","volume":"10","author":"van der Zwalul","year":"2015","journal-title":"PLoS One"},{"key":"ref191","journal-title":"Clinical breakpoints"},{"key":"ref401","article-title":"The Carbapenem Inactivation Method (CIM), a simple and low-cost alternative for the carba NP test to assess phenotypic carbapenemase activity in gram-negative rods","volume":"10","author":"van der Zwalul","year":"2015","journal-title":"PLoS One"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/1120009X.2016.1199506","article-title":"Carbapenem inactivation: a very affordable and highly specific method for phenotypic detection of carbapenemase-producing Pseudomonas aeruginosa isolates compared with other methods","volume":"29","author":"Akhi","year":"2017","journal-title":"J Chemother"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fmicb.2011.00065","article-title":"Pseudomonas aeruginosa: resistance to the max","volume":"2","author":"Poole","year":"2011","journal-title":"Front Microbiol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009\u201311 in 14 European and Mediterranean countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"e00875","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1128\/AAC.01768-15","article-title":"Comparison of verona integron-borne metallo-\u03b2-lactamase (VIM) variants reveals differences in stability and inhibition profiles","volume":"60","author":"Makena","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref431","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2017"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e01589","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant pseudomonas aeruginosa isolates from Spain","volume":"61","author":"del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","article-title":"Emergence of a new antibiotic resistance mechanism in India, Pakistan and the UK: a molecular, biological, and epidemiological study","volume":"10","author":"Kumarasamy","year":"2010","journal-title":"Lancet"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14787210.2016.1233060","article-title":"What is the role of the new \u03b2-lactam\/\u03b2-lactamase inhibitors ceftolozane\/tazobactam and ceftazidime\/avibactam?","volume":"14","author":"Gentile","year":"2016","journal-title":"Expert Rev Anti-infect Ther"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1099\/jmm.0.000927","article-title":"Acquired qnrVC1 and blaNDM-1 resistance markers in an international high-risk Pseudomonas aeruginosa ST773 clone","volume":"68","author":"Kocsis","year":"2019","journal-title":"J Med Microbiol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1128\/AAC.00296-10","article-title":"Affinity of the New Cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa","volume":"54","author":"Moy\u00e1","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2147\/DDDT.S110946","article-title":"Ceftazidime\/avibactam: a novel cephalosporin\/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections","volume":"10","author":"Hidalgo","year":"2016","journal-title":"Drug Des Dev Ther"},{"key":"ref201","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2017"},{"key":"ref381","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01117-17","article-title":"In vivo emergence of resistance to novel cephalosporin\u2013\u03b2-lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 \u03b2-lactamase (OXA-539) in sequence type 235 Pseudomonas aeruginosa","volume":"61","author":"Fraile-Ribot","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fmicb.2011.00065","article-title":"Pseudomonas aeruginosa: resistance to the max","volume":"2","author":"Poole","year":"2011","journal-title":"Front Microbiol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"e00875","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"e01858","DOI":"10.1128\/AAC.01858-17","article-title":"Activity ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref421","journal-title":"Clinical breakpoints"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1469-0691.2007.01681.x","article-title":"Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium","volume":"13","author":"Mesaros","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buerhle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","article-title":"Emergence of a new antibiotic resistance mechanism in India, Pakistan and the UK: a molecular, biological, and epidemiological study","volume":"10","author":"Kumarasamy","year":"2010","journal-title":"Lancet"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3343\/alm.2017.37.2.174","article-title":"Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of \u03b2-lactam-resistant gram-negative bacteria","volume":"37","author":"Gonzalez","year":"2017","journal-title":"Ann Lab Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e01858","DOI":"10.1128\/AAC.01858-17","article-title":"Activity ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1099\/jmm.0.000927","article-title":"Acquired qnrVC1 and blaNDM-1 resistance markers in an international high-risk Pseudomonas aeruginosa ST773 clone","volume":"68","author":"Kocsis","year":"2019","journal-title":"J Med Microbiol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"J Diag Microb Infect Dis"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"J Diag Microb Infect Dis"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/jac\/dkx253","article-title":"Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane\/tazobactam and comparison of different susceptibility testing methods","volume":"72","author":"Schaumberg","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehman","year":"2013","journal-title":"J Bio Chem"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2147\/DDDT.S110946","article-title":"Ceftazidime\/avibactam: a novel cephalosporin\/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections","volume":"10","author":"Hidalgo","year":"2016","journal-title":"Drug Des Dev Ther"},{"key":"ref151","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01117-17","article-title":"In vivo emergence of resistance to novel cephalosporin\u2013\u03b2-lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 \u03b2-lactamase (OXA-539) in sequence type 235 Pseudomonas aeruginosa","volume":"61","author":"Fraile-Ribot","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1128\/AAC.00296-10","article-title":"Affinity of the New Cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa","volume":"54","author":"Moy\u00e1","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3343\/alm.2017.37.2.174","article-title":"Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of \u03b2-lactam-resistant gram-negative bacteria","volume":"37","author":"Gonzalez","year":"2017","journal-title":"Ann Lab Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009\u201311 in 14 European and Mediterranean countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J Antimicrob Chemother"}],"container-title":["Acta Microbiologica et Immunologica Hungarica"],"original-title":[],"link":[{"URL":"https:\/\/www.akademiai.com\/doi\/full-xml\/10.1556\/030.2020.01152","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/67\/1\/article-p61.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/67\/1\/article-p61.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T23:48:47Z","timestamp":1651535327000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/67\/1\/article-p61.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":46,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1556\/030.2020.01152","relation":{},"ISSN":["1217-8950","1588-2640"],"issn-type":[{"value":"1217-8950","type":"print"},{"value":"1588-2640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}